Literature DB >> 6202615

Clinicopathological features of hepatocellular carcinoma--comparison of hepatitis B seropositive and seronegative patients.

H Okuda, H Obata, Y Motoike, T Hisamitsu.   

Abstract

Clinicopathological features were studied in 113 non-alcoholic patients with histology-proven hepatocellular carcinoma, of whom 35 were positive for hepatis B virus surface antigen (HBsAg), 23 were negative for all seromarkers for hepatitis B virus, and 55 were negative for HBsAg, but positive for anti-HBs and/or anti-core antibody (anti-HBc) with low titers. It was found that the age of the patient at the time of diagnosis was significantly lower in HBsAg cases than in the other two groups. Serum alpha-fetoprotein levels were often normal or below 100 ng/ml in the seronegative cases, and its measurement less frequently served as a diagnostic clue. Otherwise, clinically there was no difference between the three groups except for more frequent liver disease within the second degree of kinship in the HBsAg patients. Histopathological study of the livers showed that there were more expanding type hepatocellular carcinomas in the seronegative cases as compared with the HBsAg positive cases. There was no autoimmune chronic liver disease in these patients. These observations and data seem to indicate that there are certain differences between HBsAg positive and seronegative hepatocellular carcinomas. Since most patients had progressive liver disease, it is likely that many of these seronegative cases had chronic non-A, non-B viral disease, which is very common in Japan. It may be inferred further that non-A, non-B hepatitis virus is less carcinogenic as compared with hepatitis B virus.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6202615

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  9 in total

Review 1.  Non-A, non-B hepatitis.

Authors:  T N Dewar
Journal:  West J Med       Date:  1990-08

2.  Clinical features of hepatitis B virus-related hepatocellular carcinoma.

Authors:  Toru Ishikawa
Journal:  World J Gastroenterol       Date:  2010-05-28       Impact factor: 5.742

Review 3.  Hepatitis C virus infection in the elderly. Epidemiology, prophylaxis and optimal treatment.

Authors:  J Hayashi; S Kashiwagi
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

4.  Detection of HBV DNA in non-A, non-B hepatic tissues using the polymerase chain reaction assay.

Authors:  S Ohkoshi
Journal:  Gastroenterol Jpn       Date:  1991-12

5.  Reduction of synonymous substitutions in the core protein gene of hepatitis C virus.

Authors:  Y Ina; M Mizokami; K Ohba; T Gojobori
Journal:  J Mol Evol       Date:  1994-01       Impact factor: 2.395

6.  Antibody to hepatitis C virus in risk groups in Canada.

Authors:  R Chaudhary; T Mo
Journal:  Can J Infect Dis       Date:  1992-01

7.  Hepatitis C virus infection is associated with the development of hepatocellular carcinoma.

Authors:  I Saito; T Miyamura; A Ohbayashi; H Harada; T Katayama; S Kikuchi; Y Watanabe; S Koi; M Onji; Y Ohta
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

8.  Association between hepatitis C and hepatocellular carcinoma.

Authors:  Luis Jesuino de Oliveria Andrade; Argemiro D'Oliveira; Rosangela Carvalho Melo; Emmanuel Conrado De Souza; Carolina Alves Costa Silva; Raymundo Paraná
Journal:  J Glob Infect Dis       Date:  2009-01

Review 9.  Natural history of hepatitis-related hepatocellular carcinoma.

Authors:  David-Yiu-Kuen But; Ching-Lung Lai; Man-Fung Yuen
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.